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A single multilocus sequence typing (MLST) scheme was developed for precise characterization of the
opportunistic pathogens of Burkholderia cepacia complex (BCC), a group composed of at least nine closely
related species. Seven conserved housekeeping genes were selected after a comparison of five Burkholderia
species, and a collection of strains was subjected to nucleotide sequence analysis using a nested PCR ampli-
fication approach for each gene. MLST differentiated all nine current BCC species and identified 114 sequence
types within a collection of 119 strains. No differentiation was found between strains recovered from environ-
mental or clinical sources. The improved resolution in strain identification offered by MLST was able to
identify previously characterized epidemic strain lineages and also demonstrated the presence of four novel
potential species groups within the complex. There was also evidence for recombination having an important
role in the recent evolution of individual BCC species. This highly transferable, validated, MLST scheme
provides a new means to assist in species identification as well as unambiguous strain discrimination of the
BCC by a single approach. It is also the first MLST scheme designed at the outset to incorporate multiple
species and should facilitate global epidemiological investigations of the BCC.
The Burkholderia cepacia complex (BCC) is a closely related
group of gram-negative bacteria found in many niches of both
natural and clinical environments. Their classification has un-
dergone considerable taxonomic changes over the last two
decades (6, 35), and the group is now known to encompass at
least nine distinct species whose laboratory identification can
often prove difficult. Members of the BCC are opportunistic
pathogens, capable of causing disease in plants, invertebrates,
animals, and humans (3, 8, 16, 29). They can be particularly
devastating, highly virulent, cystic fibrosis (CF) pathogens (20)
that are also able to cause nosocomial infections among other
groups of debilitated patients (14, 18). Due to the high intrinsic
resistance of the BCC to antibiotics and antimicrobial com-
pounds, all of these infections can prove very difficult to treat
and may be fatal (1). All nine species have been found to
possess strains capable of causing colonization in CF patients
(4, 6, 33). The genetic diversity of the BCC is such that multiple
diagnostic tests are necessary for accurate characterization,
and difficulties with strain identification mean that misidenti-
fication can easily occur, with possible major implications for
patient care (25, 26). There is also a need for surveillance of
epidemic strains when outbreaks occur, and stringent infection
control measures already exist as an unfortunate necessity to
protect vulnerable members of the community (30).
Various molecular typing methods are currently utilized for
the discrimination of the BCC. Techniques using the single
locus of the recA gene, such as restriction fragment length
polymorphisms (RFLP), are transferable but offer limited res-
olution and are primarily applied as a means of identification
at the BCC species level (21). Other techniques used to dis-
criminate beyond the species level include multilocus restric-
tion typing, pulsed-field gel electrophoresis (PFGE), random
amplified polymorphic DNA (RAPD), and BOX-PCR (5);
how these methods are applied is dependent upon the organ-
isms being investigated and the questions being addressed by
the study. The PCR-based techniques, such as BOX-PCR and
RAPD, are highly discriminatory but not always easily trans-
ferable between different laboratories. PFGE is also not always
a transferable technique, requiring some degree of specialty
both in equipment and in use. Multilocus restriction typing
offers superior strain discrimination over single-locus RFLP by
analyzing multiple genes, but these pattern-matching tech-
niques based on gel banding have inherent variability and
ambiguities (5).
A relatively new technique that is fast becoming the “gold
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standard” of bacterial typing methods is multilocus sequence
typing (MLST) (24). It has been successfully applied to many
clinically problematic species, several of which are prominent
as respiratory pathogens, such as Streptococcus pneumoniae
(11), Pseudomonas aeruginosa (10), and Haemophilus influen-
zae (27), and even to the highly pathogenic Burkholderia
pseudomallei and Burkholderia mallei species, which are closely
related to the BCC (12). Previously MLST schemes have been
optimized to type a single species, whereas here we report the
development of a single robust MLST scheme and database
that encompasses all of the nine known BCC species, enabling
improved identification of this complex group at both the spe-
cies and strain levels within a single approach.
MATERIALS AND METHODS
Bacterial strains. BCC strains were obtained from the Belgium Co-ordinated
Collection of Micro-organisms LMG Bacteria collection, Cardiff University col-
lection (23), the U.S. B. cepacia Research Laboratory and Repository (19), and
representatives of the published strain panels (7, 23). They covered a time period
of the last 16 years from different continents. Culture and genomic DNA extrac-
tion were performed as described previously (22, 23). In addition, all isolates
were genetically typed by either RAPD (22) or PFGE (21) prior to inclusion in
the study to avoid unnecessary duplication of isolates of the same genotype.
Unless otherwise stated, all chemicals were purchased from Sigma-Aldrich Com-
pany Ltd., Poole, Dorset, United Kingdom.
Gene locus amplification. Amplification primers were designed using available
genome sequence data for the three BCC strains (Burkholderia cenocepacia
strain J2315 [http://www.sanger.ac.uk/Projects/B_cenocepacia/], B. cepacia strain
ATCC 17760 [http://genome.jgi-psf.org/draft_microbes/bur94/bur94.home.html],
and Burkholderia vietnamiensis strain G4 [http://genome.jgi-psf.org/draft_microbes
/bur08/bur08.home.html]), B. pseudomallei strain K96243 (http://www.sanger.ac.uk
/Projects/B_pseudomallei) (13), and B. mallei strain 23344 (http://www.tigr.org/msc
/mallei.shtml) (28). The genes selected for MLST were atpD, gltB, gyrB, recA, lepA,
phaC, and trpB, as shown in Table 1. The genes gltB and lepA have been previously
utilized for the MLST scheme developed for B. pseudomallei and B. mallei (29),
though we have used a different portion of each gene.
For each locus, primers were designed to have a similar melting temperature
(Tm) and were found to be successfully amplified by PCR over a wide range of
annealing temperature conditions (50 to 60°C) for a diverse panel of BCC
strains. Reaction conditions for all the primers were as follows: initial denatur-
ation at 94°C for 2 min; 30 cycles of denaturation at 94°C for 1 min, primer
annealing at 58°C for 1 min, and extension at 72°C for 2 min; followed by a final
extension step of 72°C for 5 min. Each 50-l amplification reaction mixture
comprised10 ng chromosomal DNA, 20 pmol forward and reverse primer, and
1 PCR buffer (QIAGEN, Crawley, United Kingdom) containing 1.5 mM
MgCl2, 0.8 mM deoxynucleotide triphosphates, and 1.25 U Taq (QIAGEN). The
amplification product was then purified using MinElute UF plates (QIAGEN)
following the manufacturer’s protocol before being used in a sequencing reac-
tion.
Multilocus sequence typing. Internal nested primers were designed for se-
quencing in the same manner as the amplification primers (Table 1). Using these
primers, nucleotide sequences were determined at least once on each DNA
strand with the BigDye Terminator ready reaction mix, version 3.1 (PE Biosys-
tems, Foster City, Calif.) under standard sequencing conditions according to the
manufacturer’s protocol. Unincorporated dye terminators were removed by pre-
cipitation with 95% alcohol. The reaction products were separated and detected
on an ABI PRISM genetic analyzer 3100 (PE Biosystems) using a standard
sequencing module with a performance-optimized polymer and 5-cm array. The
sequences from both strands of a given locus of the same isolate were aligned,
trimmed to the desired length (Table 2), and edited using SeqMan II (DNA Star
software).
Phylogenetic analysis. To construct gene trees of the concatenated sequences
(2,773 bp) for each isolate, the Jukes-Cantor neighbor-joining method was used
(MEGA version 3; http://www.megasoftware.net). The significance of branching
within the trees was evaluated by bootstrap analysis of 1,000 computer-generated
trees. To calculate the index of association for the different BCC species, the
LIAN program (version 3.1) (http://adenine.biz.fh-weihenstephan.de/lian/) was
used. The software program START (http://www.mlst.net) (15) was used for all
analyses unless otherwise stated.
RESULTS
Selection of gene loci and chromosomal mapping. Several
criteria were used in the selection of all potential loci. Genes
included were those encoding putative housekeeping products
necessary for biological roles in DNA repair, replication, and
amino acid biosynthesis. Genes that were either located near
or implicated as being putative virulence factors and mobile
elements were avoided, since these may come under greater
selective evolutionary pressures than other genes. The selected
loci were distributed as much as possible across the chromo-
some to ensure that each locus was genetically unlinked. Each
gene was also required to be approximately 500 bp in length to
facilitate the design of universal nested primers for each locus,
preferably in conserved flanking regions around a variable
central core.
Development of the MLST scheme for the BCC. Of the loci
chosen for the MLST scheme, atpD, gltB, gyrB, recA, lepA, and
phaC were located on the largest BCC chromosome, which
TABLE 1. Oligonucleotide nested primer sequences for the amplification and sequencing of the seven loci from genes in the BCCa
Gene (gene label) Putative gene product Chromosome location(bp)
Gene size
(bp)
Locus primer (533)
Amplification Sequencing
atpD (BCAL0036) ATP synthase 
chain
Chr.1: 38673–40067 1,395 GATCGTACAGTGCATCGG GTTCATCTGGCCGTACAC
ATCGTGCCGACCATGTAG AACTGACGCTCGAAGTCC
gltB (BCAL0289) Glutamate synthase
large subunit
Chr.1: 317771–322474 4,704 CGCTCGAAGATCAAGCAG CTTCTTCTTCGTCGCCGA
GGGAACACCTTCACGAAC TTGCCGACGTAGTCGTTG
gyrB (BCAL0421) DNA gyrase B Chr.1: 463355–465829 2,475 CGACAACTCGATCGACGA ATCGTGATGACCGAGCTG
GACAGCAGCTTGTCGTAG CGTTGTAGCTGTCGTTCC
recA (BCAL0953) Recombinase A Chr.1:1041142–1042212 1,071 GATAGCAAGAAGGGCTCC TGACCGCCGAGAAGAGCAAb
CTCTTCTTCGTCCATCGCCTCc GACCGAGTCGATGACGAT
lepA (BCA1003) GTP binding protein Chr.1:1089631–1091424 1,794 CGACGGCAAGGTCTACAA GGCATCAAGGAACTGACG
AGCATGTCGACCTTCACG CTGCGGCATGTACAGGTT
phaC (BCAL1861) Acetoacetyl-CoA
reductase
Chr.1:2051988–2052728 741 CTCAGCGAATTGCGTACG AGACGGCTTCAAGGTGGT
CCGTTCAGCGAGAAGTCG ACACGGTGTTGACCGTCA
trpB (BCAM0991) Tryptophan synthase
subunit B
Chr.2:1098142–1099335 1,194 GATCTACCTGAAGCGCGA CTGGGTCACGAACATGGA
GTGTGCATGTCCTTGTCG CCGAATGCGTCTCGATGA
a With gene number and location of gene within the genome of the B. cenocepacia strain J2315. Chr.1, largest chromosome; Chr.2, second-largest chromosome in
the J2315 strain genome.
b BCR1.
c BCR2 (21).
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appears to contain the majority of housekeeping genes. The
remaining seventh locus (trpB) was chosen from the second-
largest chromosome to ensure that the MLST scheme encom-
passed some of the diversity within other chromosomes of the
multireplicon BCC. The chromosomal locations of all these
loci were confirmed by bioinformatics analysis of the J2315
genome sequence (NC_004503 [http://www.sanger.ac.uk
/Projects/B_cenocepacia/]). The putative gene products, gene
sizes, and location within the J2315 genome are shown in Table
1.
Allelic variation. Since MLST uses multiple loci in its anal-
ysis, a greater degree of variation and therefore better resolu-
tion for typing BCC members and for inferring evolutionary
and epidemiological relatedness can be obtained than with a
single locus alone.
Novel sequence information for all seven loci was obtained
from a collection of 119 BCC strains. To assess the perfor-
mance of the MLST scheme, BCC strains were selected to be
representative of the species and genetic diversity of the com-
plex (evaluated in previous molecular epidemiological studies
[7, 19, 23]) and were also distributed both temporally and
geographically in terms of their isolation. The collection also
comprised 74 isolates of clinical origin and 45 isolates recov-
ered from environmental sources (Table 3). In silico sequence
data were also obtained for all the loci from B. pseudomallei
strain K96243 (NC_002930 [http://www.sanger.ac.uk/Projects
/B_pseudomallei] [13]), B. mallei strain 23344 (NC_002970
[http://www.sanger.ac.uk/Projects/B_mallei] [28]), “Burkhold-
eria” strain SAR-1, a metagenome from the Sargasso Sea (NS
_000028 [http://www.ncbi.nlm.nih.gov/genomes/static/es.html]
[34a]), and Burkholderia xenovorans, strain LB400 (NZ_
AAAJ00000000 [http://genome.jgi-psf.org/finished_microbes
/burfu/burfu.home.html]). The latter strain sequence data were
used to root the data set.
The mean allele length was 396 bp for the scheme and
ranged between 301 bp (trpB) and 454 bp (gyrB)(Table 2). All
alleles within a particular locus were found to be of identical
lengths for all BCC strains and the non-BCC Burkholderia
species examined, with the only exception being B. xenovorans
strain LB400 at the atpD locus, where an in-frame deletion of
24 bp was detected. Nucleotide sequence diversity was found
to be extensive at all seven loci, as shown in Table 2. The
proportion of variable sites varied from 13.1% (atpD) to 37.4%
(gyrB), which extended over the whole section of the se-
quenced allele. The polymorphic sites within the phaC locus
are shown as an example of the allelic diversity observed (Fig.
1).
Allele variation is not necessarily equally likely at every
nucleotide of each locus. If a locus does not have a role af-
fected by selective pressure (such as antibiotic exposure), then
nucleotide substitutions would frequently not be expected to
change the amino acid sequence (synonymous), since changes
are likely to be eliminated by purifying selection. By calculating
the dN/dS ratio (nonsynonymous substitutions to synonymous
substitutions), the degree of selection operating on each locus
can be estimated. The dN/dS ratio for all seven loci within BCC
strains was found to be significantly less than 1 (Table 2),
indicating that no strong positive selective pressure was
present at any of the loci selected, validating their suitability
for inclusion in the BCC MLST scheme.
Assignment of allele and sequence types (ST). Each distinct
sequence (allele sequence) at a particular locus was assigned a
unique arbitrary number (allele type). The numbers of differ-
ent alleles resolved from this BCC MLST scheme at each locus
ranged from 70 (atpD) to 92 (gyrB). The mean number of allele
types per locus was found to be 79.6, providing the potential
for distinguishing 2.0  1013 different genotypes within the
BCC and also making it highly unlikely that identical STs
would be obtained by chance.
After sequencing and assignment of allele types to all seven
loci, each strain was then designated by a combination of seven
numbers, called an allelic profile, in the order atpD, gltB, gyrB,
recA, lepA, phaC, and trpB, which represented an ST for that
particular strain (e.g., ST-1). Subsequent isolates with an iden-
tical allelic profile were assigned the same ST identifier and
considered to be isogenic as they were indistinguishable at all
seven loci.
For the development of the MLST scheme, it was important
to use a diverse collection of strains to obtain primarily differ-
ent STs (based upon known recA sequence or recA-RFLP
profiles) to validate the scheme’s effectiveness across the whole
of the BCC. A total of 114 STs were found for the 119 strains
examined (Table 3); 114 were present only once, with ST-104
occurring twice and ST-28 occurring 5 times for 5 strains of the
ET12 lineage (J2315, P1-1, LMG13307, LMG13316, and
LMG13327).
The sequences of each allele type at all seven loci, along with
the allelic profiles and sequence types for the MLST of the
BCC strains examined, are available at http://pubmlst.org/bcc/.
TABLE 2. Analysis of the seven MLST loci in the BCC strains sampled
Gene
Size (bp) of
fragment
analyzed
No. of alleles No. of polymorphicsites
Proportion of
polymorphic
sites (%)
Mean GC
content (%) dN/dS
atpD 443 70 58 13.1 62.2 0.109
gltB 400 88 101 25.3 67.6 0.098
gyrB 454 92 170 37.4 62.6 0.126
recA 393 78 105 26.7 67.9 0.049
lepA 397 79 130 32.7 65.4 0.118
phaC 385 71 84 21.8 60.9 0.040
trpB 301 79 84 27.9 69.5 0.068
Mean 396 79.6 105 26.5 65.2 0.087
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TABLE 3. MLST analysis of the BCC strains showing their sources, geographic locations, and speciesa
Strain group or ST Strain Source recARFLP Location
Allelic profile
atpD gltB gyrB recA lepA phaC trpB
B. cepacia, genomovar I
1 ATCC 17759* ENV E Trinidad 1 1 1 1 2 1 1
2 LMG 17997* NON E Sweden 2 2 2 2 1 2 2
3 BCC0464 CF E Italy 2 54 43 37 38 62 48
4 BCC0116 CF E USA 2 57 115 37 1 93 101
5 LMG 18821* CF E Australia 4 3 40 3 3 3 53
6 AU0113 CF E USA 66 109 49 3 3 40 53
7 BCC0240 NON E USA 75 58 48 37 3 3 21
8 BCC0412 ENV E Italy 6 59 50 76 44 39 51
9 BCC0227 NON E Canada 91 93 96 103 42 1 21
10 ATCC 25416T* ENV D USA 5 4 44 4 4 4 48
11 ATCC 49709 ENV D USA 24 94 125 53 41 94 102
12 BCC0218 CF D Australia 72 53 46 73 34 38 51
13 BCC0394 NON D Japan 78 55 45 37 40 37 50
14 IST431 CF AG Portugal 6 52 3 5 5 5 3
B. multivorans, genomovar II
15 LMG 18825* CF F UK 8 5 5 7 7 42 5
16 BCC0300 CF F France 8 5 5 7 7 42 105
17 BCC0149 CF F USA 97 50 4 79 37 63 55
18 C1962* NON F UK 9 75 54 93 63 35 66
19 C5393* CF F Canada 12 6 118 9 7 100 6
20 BCC0321 ENVH F UK 12 50 52 78 37 35 54
21 ATCC 17616* ENV F USA 13 78 100 94 92 96 6
22 BCC0317 ENV F Canada 13 63 53 80 61 96 56
23 BCC0281 CF R USA 7 111 4 6 6 12 4
24 BCC0066 CF R Canada 80 61 97 11 64 96 104
25 AU0066 CF O USA 10 60 4 77 37 35 5
26 BCC0497 CF O UK 13 9 83 12 7 42 7
27 C1576* CF C UK 13 7 6 10 8 42 6
B. cenocepacia, genomovar III-A
28 J2315* CF G UK 15 11 9 14 11 6 12
28 LMG 13316 CF G UK 15 11 9 14 11 6 12
28 LMG 13307 CF G UK 15 11 9 14 11 6 12
28 LMG 13327 CF G UK 15 11 9 14 11 6 12
28 BCC0711 CF G UK 15 11 9 14 11 6 12
29 C5424* CF G Canada 15 11 9 14 11 88 12
30 K56-2* CF G Canada 21 11 13 14 11 6 12
31 BC7* CF G Canada 15 11 9 14 11 6 79
32 POPR8 ENV G Mexico 16 11 10 14 11 6 79
33 BCC0560 CF G Canada 16 11 10 95 11 6 79
B. cenocepacia, genomovar III-B
34 J415* CF H UK 17 107 119 15 93 6 13
35 C1394* CF H UK 17 13 12 17 66 6 11
36 ATCC 17765* NON H UK 23 16 86 20 69 8 14
37 BC-1 ENV H USA 17 65 57 15 69 8 14
38 M36 ENV I USA 17 15 120 69 68 46 14
39 CEP0511* CF I Australia 16 108 121 49 94 41 9
40 PC184* CF J USA 17 15 85 19 68 41 13
41 BCC0491 CF J Canada 77 64 56 19 79 41 13
42 AU0787 CF AQ USA 17 97 104 58 80 76 60
43 IST452 CF AN Portugal 67 98 59 68 47 6 19
B. cenocepacia, genomovar III-C
44 LMG 19230 ENV H2 France 65 49 41 47 33 36 44
45 LMG 19238 ENV H2 Australia 62 112 92 47 99 36 87
B. cenocepacia, genomovar III-D
46 BCC0458 CF U Italy 55 39 32 39 24 30 38
B. cenocepacia, genomovar III-E
47 BCC0276 ENV V USA 53 147 33 38 23 96 46
48 MRL-10 ENV V USA 87 38 73 38 56 8 47
49 BCC0517 ENV V USA 53 40 33 38 23 30 46
B. stabilis, genomovar IV
50 LMG 14294* CF J Belgium 26 18 14 21 70 10 16
51 ATCC 35254 ENVH J USA 26 18 42 21 70 10 16
52 BCC0248 CF J New Zealand 25 18 42 21 70 10 16
53 BCC0717 CF J UK 25 69 61 109 70 10 62
54 ATCC 27515 NON J UK 25 68 60 109 70 43 61
55 BCC0418 NON J Italy 25 70 42 109 70 43 62
Continued on facing page
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TABLE 3—Continued
Strain group or ST Strain Source recARFLP Location
Allelic profile
atpD gltB gyrB recA lepA phaC trpB
B. vietnamiensis, genomovar V
56 AU0109 CF A USA 27 100 16 22 35 44 63
57 FC0441* NON A Canada 29 19 17 22 12 11 80
58 PC259* CF A USA 28 19 16 23 35 11 17
59 BCC0136 CF A Canada 27 99 15 96 36 56 17
60 G4 ENV A USA 27 20 16 48 12 11 17
61 BCC0042 ENVH AK USA 27 20 16 23 35 56 17
62 BCC0268 ENV A New Zealand 27 101 62 22 36 11 17
63 CRE-7 ENV A USA 27 19 15 22 36 11 17
64 BCC0104 NON A USA 27 19 15 22 48 11 17
65 LMG 10929T* ENV B Vietnam 27 19 15 23 35 56 17
66 BCC0128 CF B Canada 27 19 107 111 48 56 17
67 BCC0581 CF B Canada 27 103 16 23 49 56 63
68 BCC0151 CF AK USA 27 102 15 23 35 11 63
69 BCC0124 CF AK USA 27 19 87 23 12 56 81
B. dolosa, genomovar VI
70 AU0746* CF Q USA 31 22 19 25 71 13 22
71 LMG 19468 CF Q USA 30 21 127 24 72 13 20
72 LMG 18943T* CF Q USA 30 21 18 24 72 13 20
B. ambifaria, genomovar VII
73 M54* ENV L USA 32 23 20 26 13 57 23
74 ATCC 53266* ENV L USA 38 25 23 28 16 16 25
75 ATCC 53267 ENV L USA 38 25 23 28 16 16 90
76 BCC0118 CF N USA 35 25 123 98 82 79 49
77 AMMDT* ENV N USA 35 25 123 98 103 59 49
78 LMG 19467* CF N Australia 39 29 24 29 17 17 26
79 Ral-3* ENV N USA 33 86 21 50 14 58 82
80 AU1366 CF N USA 36 27 22 27 15 15 24
81 BCC0250* CF N Australia 36 26 89 99 104 90 99
82 HI-2433 ENV N USA 36 72 64 84 62 66 49
83 BCC0410 ENV N Italy 37 26 90 51 15 48 100
84 BCC0399 ENV AE Italy 74 71 63 83 50 47 64
B. anthina, genomovar VIII
85 LMG 20983* CF T UK 40 30 25 30 18 18 27
86 LMG 20980T* ENV T USA 41 31 26 31 19 19 28
87 LMG 20982* ENVH T UK 42 32 91 32 73 20 29
88 R-11761 ENV AS UK 43 33 27 104 21 21 106
89 LMG 16670* ENV AS UK 43 33 27 33 20 21 30
90 AU1293* CF AS USA 90 33 27 33 21 21 30
91 B11 ENV AH USA 44 34 124 52 95 91 83
B. pyrrocinia, genomovar IX
92 LMG 21823* ENV AR UK 51 90 94 36 77 26 35
93 AU2419* CF Sel3 USA 50 37 93 35 76 25 34
94 R-13543 ENV P USA 49 89 30 91 107 24 33
95 ATCC 39277* ENV P USA 46 36 116 107 97 92 85
BCC group K
96 IST410 CF K Portugal 89 82 80 71 60 73 74
97 CEP0964 CF K Australia 89 83 81 71 39 54 75
98 B1 ENV K USA 89 84 82 65 43 55 77
99 ATCC 17460 ENV K Trinidad 18 85 47 90 90 74 95
100 CEP1056 CF K Canada 89 114 114 66 91 98 96
101 ATCC 17760 ENV K Trinidad 63 46 38 44 30 33 42
102 SAR-1 ENV - Sargasso Sea 64 80 76 89 105 97 70
103 BCC0335 CF K Canada 68 51 78 65 58 71 71
B. cepacia complex 1
104 R-11767 CF W UK 96 118 130 112 106 99 110
104 R-11768 CF W UK 96 118 130 112 106 99 110
B. cepacia complex 2
105 BCC0110 CF H2 Canada 57 41 77 40 88 31 40
106 BCC0329 NON H2 Canada 57 41 51 40 26 31 40
107 R-9912 CF H2 Canada 92 81 39 40 89 83 41
108 ATCC 29352 ENV H2 USA 58 42 35 41 74 32 41
B. cepacia complex 3
109 LMG 14939 CF J2 Belgium 60 43 36 42 27 72 72
110 BCC0049 NON J2 Germany 60 43 36 42 27 61 72
111 J2543 ENV J2 UK 88 113 112 62 81 84 108
B. cepacia complex 4
112 T21 ENV AA USA 48 28 29 54 22 23 32
113 LMG 21824 CF AA USA 52 91 31 55 78 27 36
114 BC003 ENV AU USA 86 77 72 72 55 69 31
a An asterisk indicates the isolate is a panel strain. BCC group K, BCC group awaiting species designation (35); B. cepacia complex n, unidentified BCC groups; CF,
isolated from a CF patient; NON, isolated from a non-CF patient; ENV, isolated from the environment; ENVH, isolated from a hospital environment; USA, United
States; UK, United Kingdom.
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Analysis of recombination among the BCC. Bacteria existing
as clonal populations evolve diversity by the accumulation of
point mutations, while nonclonal populations evolve more
through recombination within or between species. In this study
identical alleles were found within species and between the
different B. cenocepacia recA subgroups but not between dif-
ferent BCC species (Table 3).
Evidence for clonal or recombining populations can be es-
timated by assessing the level of linkage between alleles at
different loci around the chromosome. The index of associa-
tion (Ia) (31) measures the extent of linkage. An Ia not signif-
icantly greater than 0 after 1,000 computer randomizations
would suggest that a single species population (monophyletic)
is in linkage equilibrium (freely recombining), while a popula-
tion with an Ia significantly greater than 0 (P  0.001) is
considered to be in linkage disequilibrium (clonal). Since the
BCC comprises many different species (polyphyletic), an Ia
value was not calculated for all 114 STs together; instead, each
BCC species for which there were at least 10 different STs was
examined.
Of the BCC species examined, B. vietnamiensis exhibited the
greatest evidence of recombination, with an Ia value of 	0.067
(14 STs), in contrast to Burkholderia ambifaria, which exhibited
the lowest Ia value, 2.043 (12 STs). When the B. cenocepacia
subgroups IIIA and IIIB (16 STs) were combined, the Ia value
rose from a value of 0.374 for B. cenocepacia III-B (10 STs)
alone to 1.786, confirming that IIIA and IIIB are distinct sub-
groups of B. cenocepacia. For B. cepacia (14 STs) and Burk-
holderia multivorans (13 STs), Ia values of 0.431 and 0.852 were
found, respectively. The number of STs for each species is low,
and therefore, a much larger sample size is required for a more
accurate comparison of mechanisms of evolution for each BCC
species.
Relationships among the BCC and related species using
concatenated nucleotide sequences. Comparisons of the topol-
ogy of neighbor-joining trees for the nucleotide sequence of
each individual locus (data not shown), including the trpB locus
located on the second-largest chromosome, revealed there was
a high level of congruence between the trees at the interspecies
level. The level of congruence within species varied from one
species to another, since some species showed higher levels of
congruence (e.g., Burkholderia stabilis and B. ambifaria) than
others (e.g., B. vietnamiensis and B. cenocepacia).
In order to assess all the loci together in one tree, concate-
nated nucleotide sequences were used. Analysis of the allelic
profiles by construction of an unweighted pair group method
with arithmetic mean tree was found to be inappropriate due
to the high level of variability between the alleles present at
each loci.
Concatenated nucleotide sequences (2,773 bp) for the 114
BCC STs alongside sequences for strains of B. pseudomallei, B.
mallei, and B. xenovorans were analyzed using a neighbor-
joining tree (Fig. 2), and the latter sequence was used to root
the data. The BCC strains were fully resolved, falling into a
distinctive broad cluster of strains, agreeing with the identifi-
cation of all isolates as BCC isolates prior to this study. The
BCC strains were clearly separated from B. xenovorans and
also to a much lesser extent from the B. pseudomallei and B.
mallei strains (100% bootstraps). All of the known species of
the BCC and most B. cenocepacia subgroups were clearly dis-
tinguished with 100% bootstrap values.
All of the four known recA lineages of B. cenocepacia clus-
tered into distinct groups (III-A, III-B, III-C, and III-D), each
with high bootstrap values, along with a fifth B. cenocepacia
subgroup (III-E). B. cepacia was also separated into sublin-
eages: two clusters which had been observed previously, the
type strain for B. cepacia (21) and a group K cluster (B. cepacia
group K [36] with ST-96, -97, -98, -99, -100, -101, -102, and
-103), with bootstrap values of 100% and 98%, respectively
(Fig. 2). An additional four groups containing unidentified
BCC isolates also appeared to fall outside of existing species
clusters. The first of these, called B. cepacia complex 1, was
composed of two strains of the same ST (ST-104), which
formed a separate branch from B. vietnamiensis. A second
group of four unidentified BCC isolates (ST-105, -106, -107,
and -108; B. cepacia complex 2) clustered with 100% boot-
straps from B. ambifaria. A third group, B. cepacia complex 3
(ST-109, -110, and -111), formed a cluster distinct from the
other species with a 100% bootstrap. The fourth group of
unidentified BCC isolates, B. cepacia complex 4 (ST-112, -113,
and -114), formed a separate branch in Fig. 2 from B. stabilis
and Burkholderia pyrrocinia with 100% bootstraps.
Identification of epidemic CF strains. Epidemic CF strains
previously implicated in patient-to-patient spread were also
analyzed by MLST. The strain collection contained eight iso-
lates identified as the ET12 transmissible lineage, which has
spread within the Canadian and United Kingdom CF popula-
tions (20), and all were found to be part of a closely related
FIG. 1. Polymorphic sites within the phaC locus of the MLST
scheme on the BCC.
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clonal complex. The five strains of this lineage isolated from
United Kingdom CF patients were ST-28 and were identical
at all seven MLST loci (isolates J2315, LMG 13316, LMG
13307, LMG 13327, and BCC0711) (Table 3). The three
ET12 strains obtained from Canadian CF patients, C5424,
K56-2, and BC7, were ST-29, -30, and and -31, respectively,
with each being single or double locus variants of the United
Kingdom ET12 strains (Table 3). Unique sequence types
were found for the other transmissible CF strains contained
in the Bcc strain panel (7, 23) (Table 3): the Edinburgh
outbreak B. multivorans strain (C1576) was ST-27, and the
Manchester, United Kingdom (C1394), Sydney, Australia
(CEP0511), and Cleveland, Ohio (PC184), epidemic B.
cenocepacia strains were ST-35, -39, and -40, respectively.
The strain (BCC0458) representative of the B. cenocepacia
III-D isolates that have spread among CF patients in Italy
(2) was ST-46. The transmissible BCC RFLP type K strain
recovered from multiple Portugese CF patients (9), repre-
sented by strain IST410, was found to be ST-96.
DISCUSSION
Schemes for the unequivocal typing and characterization of
isolates are essential for epidemiological and evolutionary
analysis of bacterial pathogens. Methodological differences in
many genotyping techniques for the BCC reduce the efficacy of
analyzing population genetics from one study to another.
Strain typing based on the comparison of DNA sequence con-
tent rather than genome organization or restriction fragments
is a more reliable and unambiguous indicator of strain identi-
fication, MLST is therefore highly appropriate for use on the
BCC. In addition to accurate strain typing, the MLST method
was shown to clearly differentiate all existing species in the
closely related BCC. The ability to carry out both strain dif-
ferentiation and species identification in a single approach
represents a major advance that should greatly aid the clinical
diagnosis of B. cepacia complex infection.
This BCC MLST scheme encompasses the most variable
group of organisms thus far reported using this typing method
in a single approach. MLST therefore meets a need for an
easily transferable, precise, and reproducible typing tool for all
species of the BCC. It is a simple tool that can offer a high level
of strain identification without using polyphasic techniques.
With environmental and clinical isolates still requiring com-
prehensive analysis, this study demonstrates that MLST could
be used not only to resolve the BCC species but also to effec-
tively disseminate the identity of these BCC isolates by this
simple, widely used technique that is directly comparable via
the Internet. It should provide a practical basis for multicenter
collaborative analysis in a way not previously possible. Also, by
comparison of patient information, isolate properties affecting
disease prognosis might be better understood. Examination of
the reference set of BCC strains assembled here to validate
MLST has already shown that the approach can clearly identify
epidemic CF strains and assist in the global infection control of
these pathogens.
The ability to exchange genetic material is of growing clinical
interest and concern. Recombination of even a single gene can
have profound effects, including increased resistance to anti-
microbials, vaccine immunity, and increased virulence. The low
index of association values seen for some of the BCC species
examined (B. cepacia, B. multivorans, B. cenocepacia III-B, and
B. vietnamiensis) indicates that recombination has had an im-
portant role in their long-term evolution. These recombination
events could be found among strains from different geographic
locations (ST-15 and ST-16; ST-28 and ST-29) and may not be
limited to just clinical or environmental isolates. MLST has
also shown that strains of the ET12 lineage and other major
transmissible strains constitute closely related clonal com-
plexes, correlating to the minor variations seen in macror-
estriction and RAPD analysis of these epidemic strain clusters
(22).
Conversely, a high index of association values was obtained
for B. ambifaria, implying that recombination has had less of a
role in its evolution than in that of the other BCC species
analyzed. Previous studies have reported B. stabilis to be a
highly conserved population (34), and analysis of the six STs
reported here so far concurs with this observation of clonality
(Ia value of 2.417).
Certainly systems exist in the BCC to facilitate recombina-
FIG. 2. Phylogenetic tree of concatenated nucleotide sequences
from the seven loci, using the neighbor-joining method, Jukes-Cantor.
Bootstrap values are shown for 1,000 replicates. Species names are
given, followed by their former genomovar number, with the number
of STs given in parentheses.
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tion, with an extensive presence of insertion sequences (17),
phages (32), conjugative transfer genes, and genomic islands
(35). Allele sharing has been found throughout several indi-
vidual species in this study, which implies that recombination
between different species could also be occurring. A larger
collection of strains will need to be assessed by MLST to
investigate species-to-species recombination further.
The MLST scheme reported here for the BCC provides a
population structure that is congruent with current species
assignments for the BCC, allowing unambiguous identification
at the species level. It also clearly resolves several unidentified
groups of isolates, which should serve to support any future
novel species or subgroup classification for them, thus provid-
ing a global platform from which important, high-level strain
identification and epidemiological evaluation can be facili-
tated.
Future work will include a detailed comparison between
MLST and other typing methods, such as PFGE and PCR
fingerprinting-based techniques (5). A larger study will also be
undertaken to further investigate recombination among the
different BCC species, evaluate BCC clonal complexes, exam-
ine more unidentified BCC strains, and explore isolates from
different ecological and epidemiological niches.
ACKNOWLEDGMENTS
This work was funded by the Wellcome Trust, grant number 072853
and in part by Heartlands Hospital, Birmingham.
We acknowledge the Sanger center for sequencing the J2315 B.
cenocepacia genome and also Angela Marchbank (Cardiff University),
Barry Curran, Helen Bird (Warwick University) and Lynne Richard-
son (Oxford University). This publication made use of the Burkhold-
eria cepacia complex Multi Locus Sequence Typing website (http:
//pubmlst.org/bcc/) developed by Keith Jolley (Jolley et al. 2004, BMC
Bioinformatics, 5:86) and hosted by the University of Oxford. The
development of this site has also been funded by the Wellcome Trust.
REFERENCES
1. Aaron, S. D., W. Ferris, D. A. Henry, D. P. Speert, and N. E. Macdonald.
2000. Multiple combination bactericidal antibiotic testing for patients with
cystic fibrosis infected with Burkholderia cepacia. Am. J. Respir. Crit. Care
Med. 161:1206–1212.
2. Agodi, A., E. Mahenthiralingam, M. Barchitta, V. Giannino, A. Sciacca, and
S. Stefani. 2001. Burkholderia cepacia complex infection in Italian patients
with cystic fibrosis: prevalence, epidemiology, and genomovar status. J. Clin.
Microbiol. 39:2891–2896.
3. Berriatua, E., I. Ziluaga, C. Miguel-Virto, P. Uribarren, R. Juste, S. Laevens,
P. Vandamme, and J. R. Govan. 2001. Outbreak of subclinical mastitis in a
flock of dairy sheep associated with Burkholderia cepacia complex infection.
J. Clin. Microbiol. 39:990–994.
4. Coenye, T., E. Mahenthiralingam, D. Henry, J. J. LiPuma, S. Laevens, M.
Gillis, D. P. Speert, and P. Vandamme. 2001. Burkholderia ambifaria sp.
nov., a novel member of the Burkholderia cepacia complex including bio-
control and cystic fibrosis-related isolates. Int. J. Syst. Evol. Microbiol. 51:
1481–1490.
5. Coenye, T., T. Spilker, A. Martin, and J. J. LiPuma. 2002. Comparative
assessment of genotyping methods for epidemiologic study of Burkholderia
cepacia genomovar III. J. Clin. Microbiol. 40:3300–3307.
6. Coenye, T., P. Vandamme, J. R. Govan, and J. J. LiPuma. 2001. Taxonomy
and identification of the Burkholderia cepacia complex. J. Clin. Microbiol.
39:3427–3436.
7. Coenye, T., P. Vandamme, J. J. LiPuma, J. R. Govan, and E. Mahenthiral-
ingam. 2003. Updated version of the Burkholderia cepacia complex experi-
mental strain panel. J. Clin. Microbiol. 41:2797–2798.
8. Corey, M., and V. Farewell. 1996. Determinants of mortality from cystic
fibrosis in Canada, 1970–1989. Am. J. Epidemiol. 143:1007–1017.
9. Cunha, M. V., J. H. Leitao, E. Mahenthiralingam, P. Vandamme, L. Lito, C.
Barreto, M. J. Salgado, and I. Sa-Correia. 2003. Molecular analysis of
Burkholderia cepacia complex isolates from a Portuguese cystic fibrosis cen-
ter: a 7-year study. J. Clin. Microbiol. 41:4113–4120.
10. Curran, B., D. Jonas, H. Grundmann, T. Pitt, and C. G. Dowson. 2004.
Development of a multilocus sequence typing scheme for the opportunistic
pathogen Pseudomonas aeruginosa. J. Clin. Microbiol. 42:5644–5649.
11. Enright, M. C., and B. G. Spratt. 1998. A multilocus sequence typing scheme
for Streptococcus pneumoniae: identification of clones associated with seri-
ous invasive disease. Microbiology 144:3049–3060.
12. Godoy, D., G. Randle, A. J. Simpson, D. M. Aanensen, T. L. Pitt, R. Ki-
noshita, and B. G. Spratt. 2003. Multilocus sequence typing and evolutionary
relationships among the causative agents of melioidosis and glanders, Burk-
holderia pseudomallei and Burkholderia mallei. J. Clin. Microbiol. 41:2068–
2079.
13. Holden, M. T., R. W. Titball, S. J. Peacock, A. M. Cerdeno-Tarraga, T.
Atkins, L. C. Crossman, T. Pitt, C. Churcher, K. Mungall, S. D. Bentley, M.
Sebaihia, N. R. Thomson, N. Bason, I. R. Beacham, K. Brooks, K. A. Brown,
N. F. Brown, G. L. Challis, I. Cherevach, T. Chillingworth, A. Cronin, B.
Crossett, P. Davis, D. DeShazer, T. Feltwell, A. Fraser, Z. Hance, H. Hauser,
S. Holroyd, K. Jagels, K. E. Keith, M. Maddison, S. Moule, C. Price, M. A.
Quail, E. Rabbinowitsch, K. Rutherford, M. Sanders, M. Simmonds, S.
Songsivilai, K. Stevens, S. Tumapa, M. Vesaratchavest, S. Whitehead, C.
Yeats, B. G. Barrell, P. C. Oyston, and J. Parkhill. 2004. Genomic plasticity
of the causative agent of melioidosis, Burkholderia pseudomallei. Proc. Natl.
Acad. Sci. USA 101:14240–14245.
14. Holmes, A., R. Nolan, R. Taylor, R. Finley, M. Riley, R. Z. Jiang, S. Stein-
bach, and R. Goldstein. 1999. An epidemic of Burkholderia cepacia trans-
mitted between patients with and without cystic fibrosis. J. Infect. Dis. 179:
1197–1205.
15. Jolley, K. A., E. J. Feil, M. S. Chan, and M. C. Maiden. 2001. Sequence type
analysis and recombinational tests (START). Bioinformatics 17:1230–1231.
16. King, G. M. 2003. Molecular and culture-based analyses of aerobic carbon
monoxide oxidizer diversity. Appl. Environ. Microbiol. 69:7257–7265.
17. Lessie, T. G., W. Hendrickson, B. D. Manning, and R. Devereux. 1996.
Genomic complexity and plasticity of Burkholderia cepacia. FEMS Micro-
biol. Lett. 144:117–128.
18. LiPuma, J. J. 1998. Burkholderia cepacia. Management issues and new
insights. Clin. Chest Med. 19:473–486, vi.
19. LiPuma, J. J., T. Spilker, L. H. Gill, P. W. Campbell III, L. Liu, and E.
Mahenthiralingam. 2001. Disproportionate distribution of Burkholderia ce-
pacia complex species and transmissibility markers in cystic fibrosis. Am. J.
Respir. Crit. Care Med. 164:92–96.
20. Mahenthiralingam, E., A. Baldwin, and P. Vandamme. 2002. Burkholderia
cepacia complex infection in patients with cystic fibrosis. J. Med. Microbiol.
51:533–538.
21. Mahenthiralingam, E., J. Bischof, S. K. Byrne, C. Radomski, J. E. Davies, Y.
Av-Gay, and P. Vandamme. 2000. DNA-based diagnostic approaches for
identification of Burkholderia cepacia complex, Burkholderia vietnamiensis,
Burkholderia multivorans, Burkholderia stabilis, and Burkholderia cepacia
genomovars I and III. J. Clin. Microbiol. 38:3165–3173.
22. Mahenthiralingam, E., M. E. Campbell, D. A. Henry, and D. P. Speert. 1996.
Epidemiology of Burkholderia cepacia infection in patients with cystic fibro-
sis: analysis by randomly amplified polymorphic DNA fingerprinting. J. Clin.
Microbiol. 34:2914–2920.
23. Mahenthiralingam, E., T. Coenye, J. W. Chung, D. P. Speert, J. R. Govan, P.
Taylor, and P. Vandamme. 2000. Diagnostically and experimentally useful
panel of strains from the Burkholderia cepacia complex. J. Clin. Microbiol.
38:910–913.
24. Maiden, M. C., J. A. Bygraves, E. Feil, G. Morelli, J. E. Russell, R. Urwin,
Q. Zhang, J. Zhou, K. Zurth, D. A. Caugant, I. M. Feavers, M. Achtman, and
B. G. Spratt. 1998. Multilocus sequence typing: a portable approach to the
identification of clones within populations of pathogenic microorganisms.
Proc. Natl. Acad. Sci. USA 95:3140–3145.
25. Martin, D. W., and C. D. Mohr. 2000. Invasion and intracellular survival of
Burkholderia cepacia. Infect. Immun. 68:24–29.
26. McMenamin, J. D., T. M. Zaccone, T. Coenye, P. Vandamme, and J. J.
LiPuma. 2000. Misidentification of Burkholderia cepacia in US cystic fibrosis
treatment centers: an analysis of 1,051 recent sputum isolates. Chest 117:
1661–1665.
27. Meats, E., E. J. Feil, S. Stringer, A. J. Cody, R. Goldstein, J. S. Kroll, T.
Popovic, and B. G. Spratt. 2003. Characterization of encapsulated and non-
capsulated Haemophilus influenzae and determination of phylogenetic rela-
tionships by multilocus sequence typing. J. Clin. Microbiol. 41:1623–1636.
28. Nierman, W. C., D. DeShazer, H. S. Kim, H. Tettelin, K. E. Nelson, T.
Feldblyum, R. L. Ulrich, C. M. Ronning, L. M. Brinkac, S. C. Daugherty,
T. D. Davidsen, R. T. Deboy, G. Dimitrov, R. J. Dodson, A. S. Durkin, M. L.
Gwinn, D. H. Haft, H. Khouri, J. F. Kolonay, R. Madupu, Y. Mohammoud,
W. C. Nelson, D. Radune, C. M. Romero, S. Sarria, J. Selengut, C. Shamblin,
S. A. Sullivan, O. White, Y. Yu, N. Zafar, L. Zhou, and C. M. Fraser. 2004.
Structural flexibility in the Burkholderia mallei genome. Proc. Natl. Acad.
Sci. USA 101:14246–14251.
29. O’Quinn, A. L., E. M. Wiegand, and J. A. Jeddeloh. 2001. Burkholderia
pseudomallei kills the nematode Caenorhabditis elegans using an endotoxin-
mediated paralysis. Cell Microbiol. 3:381–393.
30. Saiman, L., and J. Siegel. 2004. Infection control in cystic fibrosis. Clin.
Microbiol. Rev. 17:57–71.
4672 BALDWIN ET AL. J. CLIN. MICROBIOL.
31. Smith, J. M., N. H. Smith, M. O’Rourke, and B. G. Spratt. 1993. How clonal
are bacteria? Proc. Natl. Acad. Sci. USA 90:4384–4388.
32. Summer, E. J., C. F. Gonzalez, T. Carlisle, L. M. Mebane, A. M. Cass, C. G.
Savva, J. LiPuma, and R. Young. 2004. Burkholderia cenocepacia phage
BcepMu and a family of Mu-like phages encoding potential pathogenesis
factors. J. Mol. Biol. 340:49–65.
33. Vandamme, P., B. Holmes, M. Vancanneyt, T. Coenye, B. Hoste, R. Coop-
man, H. Revets, S. Lauwers, M. Gillis, K. Kersters, and J. R. Govan. 1997.
Occurrence of multiple genomovars of Burkholderia cepacia in cystic fibrosis
patients and proposal of Burkholderia multivorans sp. nov. Int. J. Syst.
Bacteriol. 47:1188–1200.
34. Vandamme, P., E. Mahenthiralingam, B. Holmes, T. Coenye, B. Hoste, P. De
Vos, D. Henry, and D. P. Speert. 2000. Identification and population struc-
ture of Burkholderia stabilis sp. nov. (formerly Burkholderia cepacia genomo-
var IV). J. Clin. Microbiol. 38:1042–1047.
34a.Venter, J. C., K. Remington, J. F. Heidelberg, A. L. Halpern, D. Rusch, J. A.
Eisen, D. Wu, I. Paulsen, K. E. Nelson, W. Nelson, D. E. Fouts, S. Levy,
A. H. Knap, M. W. Lomas, K. Nealson, O. White, J. Peterson, J. Hoffman, R.
Parsons, H. Baden-Tillson, C. Pfannkoch, Y. H. Rogers, and H. O. Smith.
2004. Environmental genome shotgun sequencing of the Sargasso Sea. Sci-
ence 304:66–74.
35. Vermis, K., T. Coenye, J. J. LiPuma, E. Mahenthiralingam, H. J. Nelis, and
P. Vandamme. 2004. Proposal to accommodate Burkholderia cepacia geno-
movar VI as Burkholderia dolosa sp. nov. Int. J. Syst. Evol. Microbiol.
54:689–691.
36. Vermis, K., T. Coenye, E. Mahenthiralingam, H. J. Nelis, and P. Vandamme.
2002. Evaluation of species-specific recA-based PCR tests for genomovar
level identification within the Burkholderia cepacia complex. J. Med. Micro-
biol. 51:937–940.
VOL. 43, 2005 MLST SCHEME FOR BCC 4673
